Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Apraglutide by Ironwood Pharmaceuticals for Short Bowel Syndrome: Likelihood of Approval
Apraglutide is under clinical development by Ironwood Pharmaceuticals and currently in Phase III for Short Bowel Syndrome. According to GlobalData,...
Data Insights
Risk adjusted net present value: What is the current valuation of Ironwood Pharmaceuticals's Apraglutide?
Apraglutide is a synthetic peptide commercialized by Ironwood Pharmaceuticals, with a leading Phase III program in Short Bowel Syndrome. According...